Back to resultsRole of K+ and Ca2+ in Development of Muscle Fatigue
Primary Purpose
Skeletal Muscle Fatigue in Humans
Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Terbutaline
Placebo
Sponsored by
About this trial
This is an interventional basic science trial for Skeletal Muscle Fatigue in Humans
Eligibility Criteria
Inclusion Criteria:
- physical active healthy men
- aged 18-40 years
Exclusion Criteria:
- smokers
- allergy towards terbutaline
- chronic disease
Sites / Locations
- Department of Nutrition, Exercise and Sports
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
terbutaline
Placebo
Arm Description
terbutaline is administered by injection (0.25-0.5 mg Bricanyl, AstraZeneca diluted in 9 ml isotonic saline)
placebo is administered as isotonic saline (10 ml)
Outcomes
Primary Outcome Measures
Change in time to fatigue during knee-extensor exercise
Secondary Outcome Measures
Full Information
NCT ID
NCT02712658
First Posted
October 11, 2015
Last Updated
January 29, 2017
Sponsor
University of Copenhagen
1. Study Identification
Unique Protocol Identification Number
NCT02712658
Brief Title
Role of K+ and Ca2+ in Development of Muscle Fatigue
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
September 2015 (undefined)
Primary Completion Date
March 2016 (Actual)
Study Completion Date
March 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Copenhagen
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of the study is to investigate the role of K+ and Ca2+ in development of muscle fatigue in trained young men.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Skeletal Muscle Fatigue in Humans
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
terbutaline
Arm Type
Active Comparator
Arm Description
terbutaline is administered by injection (0.25-0.5 mg Bricanyl, AstraZeneca diluted in 9 ml isotonic saline)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
placebo is administered as isotonic saline (10 ml)
Intervention Type
Drug
Intervention Name(s)
Terbutaline
Intervention Description
K+ transport and Ca2+ release and uptake function are stimulated by administration of terbutaline
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change in time to fatigue during knee-extensor exercise
Time Frame
1 day
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
physical active healthy men
aged 18-40 years
Exclusion Criteria:
smokers
allergy towards terbutaline
chronic disease
Facility Information:
Facility Name
Department of Nutrition, Exercise and Sports
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
12. IPD Sharing Statement
Learn more about this trial
Role of K+ and Ca2+ in Development of Muscle Fatigue
We'll reach out to this number within 24 hrs